Sort
82,697 grants matching “vaccine development”
BSL4 Evaluation Core
$1,755,449Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2015 · AI
Production of a Broadly Neutralizing HIV Antibody (VRC01)
$1,755,395Richard Schwartz · National Institute Of Allergy And Infectious Diseases · ZIB · FY2011 · AI
Adoptive Cell Transfer Immunotherapy of Cancer
$1,755,358Steven Rosenberg · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
COMPREHENSIVE SICKLE CELL CENTER
$1,755,211University Of Alabama At Birmingham · P60 · FY2001 · HL
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy
$1,755,184Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
The Johns Hopkins University-Blantyre Clinical Trials Unit
$1,755,125Taha E Taha · Johns Hopkins University · UM1 · FY2024 · AI
Clinical Evaluation of Novel Adenovirus Vectors
$1,754,986Raphael Dolin · Beth Israel Deaconess Medical Center · U19 · FY2009 · AI
Epithelial innate signaling in airway inflammation and remodeling
$1,754,585Roberto P Garofalo · University Of Texas Med Br Galveston · P01 · FY2021 · AI
Epithelial innate signaling in airway inflammation and remodeling
$1,754,585Roberto P Garofalo · University Of Texas Med Br Galveston · P01 · FY2022 · AI
Epithelial innate signaling in airway inflammation and remodeling
$1,754,585Roberto P Garofalo · University Of Texas Med Br Galveston · P01 · FY2020 · AI
Environmental/genetic Risk Factors and Pathogenesis of Autoimmune Disease
$1,753,797Frederick Miller · National Institute Of Environmental Health Sciences · ZIA · FY2016 · ES
Influenza responses and repertoire in vaccination, infection and tonsil organoids.
$1,753,765Mark M Davis · Stanford University · U19 · FY2021 · AI
AZD9688: A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease
$1,753,722Mark T Dransfield · University Of Alabama At Birmingham · UH3 · FY2018 · TR
COMBINATORIAL APPROACHES TO TREAT NEOPLASTIC DISEASES
$1,753,167Torrey Pines Inst For Molecular Studies · P01 · FY2001 · CA
Mayo Clinic Ovarian Cancer SPORE
$1,752,990Scott H Kaufmann · Mayo Clinic Rochester · P50 · FY2023 · CA
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity
$1,752,897Patrick Hwu · University Of Tx Md Anderson Can Ctr · P01 · FY2009 · CA
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
$1,752,798Karen L. Kotloff · University Of Maryland Baltimore · UM1 · FY2024 · AI
Production of Aluminum Based Adjuvants
$1,752,200Fred Mack · Advanced Bioscience Laboratories, Inc. · N01 · FY2017 · AI
Noroviruses and Epidemic Gastroenteritis
$1,752,004Kim Y. Green · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Molecular Biology of Francisella tularensis Virulence
$1,751,649University Of Texas Sw Med Ctr/Dallas · P01 · FY2005 · AI
IL-2IL-15 Cytokine Receptor: Implications for Cancer Therapy and Vaccine Design
$1,751,169Thomas Waldmann · Division Of Clinical Sciences - Nci · ZIA · FY2011 · CA
Interleukin-15 Production for Treatment of Patients with Metastatic Malignancy
$1,751,169Thomas Waldmann · Division Of Basic Sciences - Nci · ZIB · FY2011 · CA
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations
$1,751,091Joel Palefsky · University Of California, San Francisco · U54 · FY2021 · CA
University of Washington Arboviral Research Network (UWARN)
$1,751,002Wesley C Van Voorhis · University Of Washington · U01 · FY2020 · AI
Respiratory Immunity Against Agents of Bioterrorism
$1,750,344Wake Forest University Health Sciences · P01 · FY2005 · AI